Abstract
Targeting mitochondria respiration is an effective therapeutic strategy in renal cell carcinoma (RCC). Atovaquone is a FDA-approved antibiotic but is also known as a mitochondrial inhibitor. We found that atovaquone inhibited proliferation and induced apoptosis of RCC cells. Mechanistically, atovaquone inhibits mitochondrial respiration in a concentration-dependent and time-dependent manner, via targeting mitochondrial respiratory complex III. Although increased glycolysis was observed in atovaquone-treated cells, atovaquone decreased ATP levels. As a consequence of mitochondrial respiration inhibition, reactive oxygen species levels were increased by atovaquone. The complete rescue of atovaquone's effects by an antioxidant suggests the important role of oxidative stress in the action of atovaquone in RCC. Importantly, atovaquone enhanced the in vitro and in vivo efficacy of 5-fluorouracil (5-FU) and interferon-α (IFN-α). Our preclinical findings suggest that atovaquone is a useful addition for RCC treatment. Our work also further demonstrates that RCC is more dependent on mitochondrial respiration than glycolysis.
References
Apr 1, 1992·Biochemical Pharmacology·M Fry, M Pudney
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L M MinasianS E Krown
Feb 14, 1997·The Journal of Biological Chemistry·I K SrivastavaA B Vaidya
Dec 28, 1999·Pharmacotherapy·J FalloonH Masur
May 27, 2005·The Journal of Biological Chemistry·Michael W MatherAkhil B Vaidya
May 26, 2007·The Journal of Biological Chemistry·Jee Hyun UmJay H Chung
Nov 29, 2008·Free Radical Biology & Medicine·Enrique SamperSimon Melov
Apr 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Frank WeinbergNavdeep S Chandel
Nov 19, 2011·Cancer Cell·Marko SkrtićAaron D Schimmer
Dec 12, 2012·Oncology Letters·Jie Zheng
Jan 22, 2013·Cell Stem Cell·Eleni D LagadinouCraig T Jordan
Jan 28, 2015·Oncotarget·Rebecca LambMichael P Lisanti
Oct 17, 2015·Oncotarget·Yunseon JangGi Ryang Kweon
May 4, 2016·Oncotarget·Marco FiorilloMichael P Lisanti
Jul 28, 2016·Nature Communications·Thomas M AshtonWilliam Gillies McKenna
Mar 10, 2017·Nature Reviews. Disease Primers·James J HsiehVincenzo Ficarra
May 27, 2017·Oncotarget·Baoan HongNing Zhang
May 30, 2017·Urologic Oncology·Alp Tuna BeksacKetan K Badani
Jun 25, 2017·Biochemical and Biophysical Research Communications·Bo WangXiaobin Yao
Jul 12, 2017·Nature Reviews. Nephrology·Edwin M PosadasRobert A Figlin
Aug 15, 2017·Urologic Oncology·Ahmet BindayiIthaar H Derweesh
Aug 30, 2017·Biochemical and Biophysical Research Communications·Min ZhuZhifang Zhou
Citations
Dec 20, 2019·Blood Advances·Alexandra M StevensDavid A Frank
Jul 17, 2020·International Journal of Molecular Sciences·Federica LaudisiCarmine Stolfi
Oct 9, 2020·Journal of Experimental & Clinical Cancer Research : CR·Faiqa MudassarEric Hau
May 8, 2020·Seminars in Cancer Biology·Anuradha KirtoniaManoj Garg
Apr 2, 2021·Frontiers in Oncology·André MarquardtMarkus Krebs
Oct 27, 2020·Journal of Medicinal Chemistry·Yibin XuNouri Neamati
Jan 10, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daan F BoreelJohan Bussink
Jun 3, 2021·Pharmaceuticals·Nehal Gupta, Sanjay K Srivastava
May 18, 2021·Frontiers in Oncology·Yan-Qi LiJi-Gang Dai
Jun 16, 2021·European Journal of Pharmacology·Fan XieJingping Ma
Jun 27, 2021·Pathology, Research and Practice·Yue GuoHongyan Zhu
Oct 14, 2021·The Journal of International Medical Research·Bo WangChengjun Qiu